Eichhorst, Barbara, Fuerstenau, Moritz and Hallek, Michael (2019). Relapsed disease and aspects of undetectable MRD and treatment discontinuation. Hematol.-Am. Soc. Hematol. Educ. Program. S. 482 - 490. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1520-4383
Full text not available from this repository.Abstract
Continuous treatment vs fixed duration of monotherapies and combinations of targeted agents are treatment options in relapsed chronic lymphocytic leukemia. The optimal choice of relapse treatment is dependent on the prior frontline therapy, duration of remission after frontline, genetic markers, and patients' condition, including age and comorbidities. Combination therapies may result in deep responses with undetectable minimal residual disease (uMRD). Although uMRD is an excellent predictive marker for disease progression, it is rarely used in clinical practice and needs additional evaluation in clinical trials before discontinuation of therapy should be guided according to uMRD.
Item Type: | Journal Article | ||||||||||||||||
Creators: |
|
||||||||||||||||
URN: | urn:nbn:de:hbz:38-124963 | ||||||||||||||||
Journal or Publication Title: | Hematol.-Am. Soc. Hematol. Educ. Program | ||||||||||||||||
Page Range: | S. 482 - 490 | ||||||||||||||||
Date: | 2019 | ||||||||||||||||
Publisher: | AMER SOC HEMATOLOGY | ||||||||||||||||
Place of Publication: | WASHINGTON | ||||||||||||||||
ISSN: | 1520-4383 | ||||||||||||||||
Language: | English | ||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||
Subjects: | no entry | ||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||
Refereed: | Yes | ||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/12496 |
Downloads
Downloads per month over past year
Export
Actions (login required)
View Item |